Insulin Delivery Devices - Medical Devices Pipeline Assessment, 2019

1 Table of Contents

• 1.1 List of Tables
• 1.2 List of Figures

2 Introduction

• 2.1 Insulin Delivery Devices Overview

3 Products under Development

• 3.1 Insulin Delivery Devices - Pipeline Products by Stage of Development
• 3.2 Insulin Delivery Devices - Pipeline Products by Segment
• 3.3 Insulin Delivery Devices - Pipeline Products by Territory
• 3.4 Insulin Delivery Devices - Pipeline Products by Regulatory Path
• 3.5 Insulin Delivery Devices - Pipeline Products by Estimated Approval Date
• 3.6 Insulin Delivery Devices - Ongoing Clinical Trials

4 Insulin Delivery Devices - Pipeline Products under Development by Companies

• 4.1 Insulin Delivery Devices Companies - Pipeline Products by Stage of Development
• 4.2 Insulin Delivery Devices - Pipeline Products by Stage of Development

5 Insulin Delivery Devices Companies and Product Overview

• 5.1 Amrita Vishwa Vidyapeetham Company Overview
• 5.2 Andain, Inc Company Overview
• 5.3 Animas Corp Company Overview
• 5.4 ASTI Corp Company Overview
• 5.5 Avecho Biotechnology Ltd Company Overview
• 5.6 Becton Dickinson and Co Company Overview
• 5.7 Bigfoot Biomedical Inc Company Overview
• 5.8 Biocon Ltd Company Overview
• 5.9 Cam Med LLC Company Overview
• 5.10 Cambridge Consultants Ltd Company Overview
• 5.11 Capillary Biomedical, Inc. Company Overview
• 5.12 Cellnovo Ltd Company Overview
• 5.13 CeQur SA Company Overview
• 5.14 Companion Medical Inc Company Overview
• 5.15 Dance Biopharm Inc Company Overview
• 5.16 Debiotech SA Company Overview
• 5.17 Defymed SAS Company Overview
• 5.18 Dermisonics Inc (Inactive) Company Overview
• 5.19 Eli Lilly and Co Company Overview
• 5.20 Emperra GmbH E-Health Technologies Company Overview
• 5.21 Hospira Inc Company Overview
• 5.22 Imagine Medical Device Inc. Company Overview
• 5.23 InsuLenz Company Overview
• 5.24 Insulet Corp Company Overview
• 5.25 InsuLine Medical Ltd Company Overview
• 5.26 Iowa State University Company Overview
• 5.27 LifeScan Inc Company Overview
• 5.28 MannKind Corp Company Overview
• 5.29 Medical International Technologies (Mit Canada) Inc Company Overview
• 5.30 MedPro Safety Products, Inc. Company Overview
• 5.31 MedSolve Technologies, Inc. Company Overview
• 5.32 Medtronic Diabetes Company Overview
• 5.33 Medtronic plc Company Overview
• 5.34 MicroPort Scientific Corp Company Overview
• 5.35 NanoDerma Ltd Company Overview
• 5.36 Nitto Denko Corp Company Overview
• 5.37 North Carolina State University Company Overview
• 5.38 Novo Nordisk AS Company Overview
• 5.39 Pennsylvania State University Company Overview
• 5.40 Phluid Corporation Company Overview
• 5.41 Prometheon Pharma LLC Company Overview
• 5.42 Sanofi Company Overview
• 5.43 SFC Fluidics LLC Company Overview
• 5.44 Spring Health Solutions Ltd. Company Overview
• 5.45 Tandem Diabetes Care Inc Company Overview
• 5.46 Terumo Corp Company Overview
• 5.47 Thermalin Inc Company Overview
• 5.48 Transdermal Specialties Inc Company Overview
• 5.49 University of KwaZulu-Natal Company Overview
• 5.50 University of Missouri-Kansas City Company Overview
• 5.51 University of North Carolina Company Overview
• 5.52 University of Toronto Company Overview
• 5.53 Univlabs Technologies Pvt Ltd Company Overview
• 5.54 Valeritas Inc Company Overview
• 5.55 ViCentra BV Company Overview
• 5.56 Vigmed Holding AB Company Overview
• 5.57 WaveForm Technologies Inc Company Overview
• 5.58 Ypsomed Holding AG Company Overview
• 5.59 Zealand Pharma AS Company Overview

6 Insulin Delivery Devices - Recent Developments

• 6.1 Jun 25, 2019: ConvaTec Group: Board Change
• 6.2 Jun 17, 2019: Xeris Pharmaceuticals announces additional positive outcomes from a global phase 3 clinical trial of its investigational ready-to-use glucagon
• 6.3 Jun 17, 2019: BD announces new leadership for BD Biosciences
• 6.4 Jun 14, 2019: Biocon Biologics facilities In Bengaluru receive EU GMP Certification
• 6.5 Jun 14, 2019: Drug Makers Sue to Block requirement for Listing Prices in TV Ads
• 6.6 Jun 11, 2019: Zealand Pharma presents dasiglucagon pivotal Phase 3 trial data at the 79th Scientific Sessions of the American Diabetes Association (ADA)
• 6.7 Jun 11, 2019: Changes in Roche's board of directors and corporate executive committee
• 6.8 Jun 11, 2019: Regulators demand more details on Roche’s $4.8bn Spark acquisition
• 6.9 Jun 10, 2019: Valeritas V-Go Wearable Insulin Delivery Device demonstrates a reduction in A1c levels by 1.3 when intensifying from a basal insulin regimen to basal-bolus delivery
• 6.10 Jun 09, 2019: MannKind Presents Positive Afrezza Clinical Data from Three Studies at ADA 79th Scientific Sessions
• 6.11 Jun 07, 2019: Companion Medical announces product updates to support data partnerships and enhanced reporting
• 6.12 Jun 07, 2019: Paul Hudson to succeed Olivier Brandicourt as chief executive officer
• 6.13 Jun 06, 2019: Dexcom and Companion Medical announce collaboration to integrate Dexcom CGM data and InPen insulin data
• 6.14 Jun 06, 2019: Insulet to showcase its recently-lunched Omnipod DASH System and present seven scientific abstracts at the American Diabetes Association's 79th Scientific Sessions
• 6.15 Jun 05, 2019: CeQur appoints Bradley Paddock Chief Executive Officer
• 6.16 Jun 05, 2019: Companion Medical and Glooko announce partnership agreement to integrate insulin data for multiple daily injections
• 6.17 Jun 05, 2019: Jeff Settleman, Ph.D., joins Pfizer to lead oncology research & development
• 6.18 Jun 04, 2019: Rimidi and Companion Medical announce first U.S. partnership to bring connected Insulin data Into the clinical workflow
• 6.19 Jun 04, 2019: Medtronic awarded $150M contract from Defense Logistics Agency
• 6.20 Jun 03, 2019: Afrezza (insulin human) inhalation powder approved in Brazil

7 Appendix

• 7.1 Methodology
• 7.2 About GlobalData
• 7.3 Contact Us